Literature DB >> 26644810

Drug persistence and adherence in the treatment of overactive bladder.

Sidney B Radomski1.   

Abstract

Entities:  

Year:  2015        PMID： 26644810      PMCID： PMC4662399          DOI： 10.5489/cuaj.3367

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  5 in total

1.  Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.

Authors:  Adrian Wagg; Gerhard Compion; Amanda Fahey; Emad Siddiqui
Journal:  BJU Int       Date:  2012-03-12       Impact factor: 5.588

2.  Rate and determinants of 10-year persistence with antihypertensive drugs.

Authors:  Boris Lg Van Wijk; Olaf H Klungel; Eibert R Heerdink; Anthonius de Boer
Journal:  J Hypertens       Date:  2005-11       Impact factor: 4.844

3.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

Authors:  Bernard Vrijens; Gäbor Vincze; Paulus Kristanto; John Urquhart; Michel Burnier
Journal:  BMJ       Date:  2008-05-14

4.  Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada.

Authors:  Adrian Wagg; Billy Franks; Barbara Ramos; Todd Berner
Journal:  Can Urol Assoc J       Date:  2015 Sep-Oct       Impact factor: 1.862

Review 5.  Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-07       Impact factor: 3.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.